Product Details

Verometo is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Metoclopramide Hydrochloride for use as an antiemetic and prokinetic agent through the intramuscular (I.M.) or intravenous (I.V.) route. As a result, it offers rapid relief from nausea and vomiting along with improved gastric motility in clinical settings.

The injection contains:

• Metoclopramide Hydrochloride IP – A dopamine D2 receptor antagonist that also exerts prokinetic effects on the upper gastrointestinal tract. Consequently, it blocks the chemoreceptor trigger zone to reduce nausea and vomiting while enhancing gastric emptying and motility.

Physicians use Verometo for the management of nausea and vomiting associated with chemotherapy, radiotherapy, surgery, and migraine, as well as for the treatment of delayed gastric emptying in conditions such as diabetic gastroparesis. In addition, its dual-route (I.M./I.V.) formulation allows flexible administration based on clinical need. Because of this profile, Verometo suits hospitals and institutional healthcare settings where prompt antiemetic and prokinetic support is required.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./I.V.) formulation offers flexible clinical use
• Furthermore, each vial delivers precise, validated dosage accuracy
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected vial packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals and institutional healthcare settings